Jazz Pharmaceuticals slips 3.9% as investors appear to reposition ahead of earnings

Jazz Pharmaceuticals plc (JAZZ) is down 3.9% today. Here is some analysis on what might have caused this price movement.

Analysis: There does not appear to be a fresh company-specific setback driving the move. This could be because traders are repositioning ahead of Jazz’s November 2, 2026 third-quarter report, while also reacting to a recent analyst price-target trim and an October management-transition filing.

Details:

Jazz said on October 23 that updated ESMO 2026 data for Ziihera combinations in first-line HER2-positive gastroesophageal adenocarcinoma showed sustained survival benefit, so the decline does not look tied to a negative clinical readout.

The company said it will report third-quarter 2026 financial results on November 2, which can increase caution and profit-taking as investors weigh earnings risk.

Quote pages circulating this week showed a lower published price target than the prior figure, pointing to somewhat softer near-term expectations even though the broader analyst stance remains constructive.

An October 9 SEC filing disclosed that the chief commercial officer plans to retire after a successor is chosen or by June 30, 2027, which may be adding a small layer of uncertainty around commercial execution.

Sources:

Jazz Pharmaceuticals, SEC, Yahoo Finance

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$JAZZ Insider Trading Activity

$JAZZ insiders have traded $JAZZ stock on the open market 19 times in the past 6 months. Of those trades, 0 have been purchases and 19 have been sales.

Here’s a breakdown of recent trading of $JAZZ stock by insiders over the last 6 months:

ROBERT IANNONE (EVP, Global Head of R&D & CMO) has made 0 purchases and 6 sales selling 76,921 shares for an estimated $19,207,097.
BRUCE C COZADD has made 0 purchases and 5 sales selling 30,000 shares for an estimated $6,973,380.
SAMANTHA PEARCE (EVP, Chief Commercial Officer) sold 6,907 shares for an estimated $1,625,976
RENEE D GALA (President & CEO) has made 0 purchases and 2 sales selling 4,000 shares for an estimated $958,860.
RICK E WINNINGHAM sold 2,741 shares for an estimated $662,143
NEENA M PATIL (EVP & Chief Legal Officer) has made 0 purchases and 2 sales selling 2,392 shares for an estimated $571,596.
HEATHER ANN MCSHARRY sold 2,000 shares for an estimated $482,000
MARK DOUGLAS SMITH sold 1,157 shares for an estimated $266,746

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$JAZZ Hedge Fund Activity

We have seen 363 institutional investors add shares of $JAZZ stock to their portfolio, and 248 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 2,333,564 shares (+102.5%) to their portfolio in Q2 2026, for an estimated $562,318,917
ECOR1 CAPITAL, LLC removed 1,706,469 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $411,207,834
JPMORGAN CHASE & CO added 1,160,786 shares (+inf%) to their portfolio in Q2 2026, for an estimated $279,714,602
NORGES BANK added 656,843 shares (+inf%) to their portfolio in Q2 2026, for an estimated $158,279,457
HOLOCENE ADVISORS, LP removed 572,914 shares (-78.1%) from their portfolio in Q2 2026, for an estimated $138,055,086
MARINER, LLC added 568,599 shares (+1420.9%) to their portfolio in Q2 2026, for an estimated $137,015,301
MILLENNIUM MANAGEMENT LLC removed 498,631 shares (-39.5%) from their portfolio in Q2 2026, for an estimated $120,155,112

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$JAZZ Price Targets

Multiple analysts have issued price targets for $JAZZ recently. We have seen 10 analysts offer price targets for $JAZZ in the last 6 months, with a median target of $267.5.

Here are some recent targets:

Gregg Gilbert from Deutsche Bank set a target price of $270.0 on 07/09/2026
Gregory Renza from Truist Securities set a target price of $254.0 on 07/07/2026
Jason Gerberry from B of A Securities set a target price of $307.0 on 06/10/2026
Etzer Darout from Barclays set a target price of $253.0 on 05/27/2026
Jeffrey Walch from Bernstein set a target price of $229.0 on 05/22/2026
David Amsellem from Piper Sandler set a target price of $301.0 on 05/22/2026
Ashwani Verma from UBS set a target price of $307.0 on 05/19/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.